(Q33349428)

26 July 2017

title

Phase II study of ecteinascidin 743 in heavily pretreated patients with recurrent osteosarcoma (English)

1 reference

26 July 2017

main subject

recurrent osteosarcoma

1 reference

Paul A Meyers

5

0 references

Richard G Gorlick

object named as

Richard Gorlick

4

0 references

Robert G. Maki

object named as

Robert G Maki

6

0 references

Leonard H Wexler

7

object named as

Leonard Wexler

1 reference

26 July 2017

10

Andrew G Huvos

1 reference

26 July 2017

2

E Anders Kolb

1 reference

26 July 2017

11

Allen M Goorin

1 reference

26 July 2017

1

Caroline Laverdiere

1 reference

26 July 2017

8

George D Demetri

1 reference

26 July 2017

Jeffrey G Supko

3

1 reference

26 July 2017

John H Healey

9

1 reference

26 July 2017

Rochelle Bagatell

12

1 reference

26 July 2017

Ana Ruiz-Casado

13

1 reference

26 July 2017

Cecilia Guzman

14

1 reference

26 July 2017

Jose Jimeno

15

1 reference

26 July 2017

David Harmon

16

1 reference

26 July 2017

language of work or name

English

0 references

publication date

1 August 2003

1 reference

26 July 2017

1 reference

26 July 2017

volume

98

1 reference

26 July 2017

issue

4

1 reference

26 July 2017

page(s)

832-840

1 reference

The contribution of salvage surgery to the management of childhood osteosarcoma

26 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11563

7 January 2021

Osteosarcoma recurrences in pediatric patients previously treated with intensive chemotherapy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11563

7 January 2021

Systemic relapse of patients with osteogenic sarcoma. Prognostic factors for long term survival

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11563

7 January 2021

Ifosfamide and etoposide in childhood osteosarcoma. A phase II study of the French Society of Paediatric Oncology

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11563

7 January 2021

Long-term follow-up and post-relapse survival in patients with non-metastatic osteosarcoma of the extremity treated with neoadjuvant chemotherapy.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11563

7 January 2021

Ifosfamide/etoposide alternating with high-dose methotrexate: evaluation of a chemotherapy regimen for poor-risk osteosarcoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11563

7 January 2021

High-dose chemotherapy in the treatment of relapsed osteosarcoma: an Italian sarcoma group study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11563

7 January 2021

Treatment of refractory osteosarcoma with fractionated cyclophosphamide and etoposide

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11563

7 January 2021

Ecteinascidins 729, 743, 745, 759A, 759B, and 770: potent antitumor agents from the Caribbean tunicate Ecteinascidia turbinata

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11563

7 January 2021

Additional antitumor ecteinascidins from a Caribbean tunicate: crystal structures and activities in vivo

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11563

7 January 2021

In vitro antitumor activity of the novel marine agent, ecteinascidin-743 (ET-743, NSC-648766) against human tumors explanted from patients

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11563

7 January 2021

High antitumour activity of ET743 against human tumour xenografts from melanoma, non-small-cell lung and ovarian cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11563

7 January 2021

In vitro schedule-dependency of myelotoxicity and cytotoxicity of Ecteinascidin 743 (ET-743).

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11563

7 January 2021

DNA sequence- and structure-selective alkylation of guanine N2 in the DNA minor groove by ecteinascidin 743, a potent antitumor compound from the Caribbean tunicate Ecteinascidia turbinata

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11563

7 January 2021

Poisoning of human DNA topoisomerase I by ecteinascidin 743, an anticancer drug that selectively alkylates DNA in the minor groove

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11563

7 January 2021

Ecteinascidin 743: a minor groove alkylator that bends DNA toward the major groove

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11563

7 January 2021

Ecteinascidin 743, a transcription-targeted chemotherapeutic that inhibits MDR1 activation

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11563

7 January 2021

Interference of transcriptional activation by the antineoplastic drug ecteinascidin-743.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11563

7 January 2021

Increased DNA Binding Specificity for Antitumor Ecteinascidin 743 through Protein−DNA Interactions?

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11563

7 January 2021

Differential cytostatic and apoptotic effects of ecteinascidin-743 in cancer cells. Transcription-dependent cell cycle arrest and transcription-independent JNK and mitochondrial mediated apoptosis.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11563

7 January 2021

Characterisation of antimitotic products from marine organisms that disorganise the microtubule network: ecteinascidin 743, isohomohalichondrin-B and LL-15.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11563

7 January 2021

Antiproliferative activity of ecteinascidin 743 is dependent upon transcription-coupled nucleotide-excision repair.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11563

7 January 2021

The inefficiency of incisions of ecteinascidin 743-DNA adducts by the UvrABC nuclease and the unique structural feature of the DNA adducts can be used to explain the repair-dependent toxicities of this antitumor agent

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11563

7 January 2021

Ecteinascidin-743 (ET-743), a natural marine compound, with a unique mechanism of action.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11563

7 January 2021

Unique features of the mode of action of ET-743.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11563

7 January 2021

One of the most interesting pro-apoptotic proteins recently identified is the TNF-related apoptosis-inducing ligand (TRAIL)

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11563

7 January 2021

Phase I and pharmacokinetic study of ecteinascidin-743, a new marine compound, administered as a 24-hour continuous infusion in patients with solid tumors.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11563

7 January 2021

Pharmacokinetics of ecteinascidin 743 administered as a 24-h continuous intravenous infusion to adult patients with soft tissue sarcomas: associations with clinical characteristics, pathophysiological variables and toxicity

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11563

7 January 2021

Treatment of osteosarcoma with ifosfamide: comparison of response in pediatric patients with recurrent disease versus patients previously untreated: a Pediatric Oncology Group study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11563

7 January 2021

The orphan nuclear receptor SXR coordinately regulates drug metabolism and efflux

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11563

7 January 2021

Cytotoxic agents in the era of molecular targets and genomics

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11563

7 January 2021

Identifiers

DOI

10.1002/CNCR.11563

1 reference

26 July 2017

1 reference